----

| Colorado                                            | 0-31743                       | 84-1536517                                |
|-----------------------------------------------------|-------------------------------|-------------------------------------------|
| (State or other jurisdiction of      incorporation) | (Commission File      Number) | (IRS Employer Identification      Number) |
|                                                |                          |
| 1117 Herkimer Street, Houston,      Texas           | 77008                         |
| (Address of principal executive      offices)       | (Zip  Code)                   |

----

----

|   |                  INTERACTIVE      THERAPEUTICS, INC. |
|--------|-------------------------------------------------------------------------------------------------------------------------------------------|

| Part I  | Financial      Information |
|---------|----------------------------|
|    |                       |   |   |
|    |                       |   |   |
|    | Item 1.                    | Financial      Statements |   |
|    |                       |   |   |
|    |                       | Consolidated Balance Sheets      September 30, 2007 (unaudited) |   |
|    |                       |      and      March 31, 2007 | 3 |
|    |                       |   |   |
|    |                       | Consolidated Statements of      Operations (unaudited) |   |
|    |                       |     Three and      Six Ended Months September 30, 2007 and 2006 |   |
|    |                       |     Inception      (February 15, 2005) through September 30, 2007 | 4 |
|    |                       |   |   |
|    |                       | Consolidated Statements of Cash      Flows (unaudited) |   |
|    |                       |     Six Months      Ended September 30, 2007 and 2006 |   |
|    |                       |     Inception      (February 15, 2005) through September 30, 2007 | 5 |
|    |                       |   |   |
|    |                       | Notes to Unaudited Consolidated      Financial Statements | 6 |
|    |                       |   |   |
|    | Item 2.                    | Management’s Discussion and      Analysis of Results of |   |
|    |                       |    Operations and      Financial Condition | 9 |
|    |                       |   |   |
|    | Item 3.                    | Controls and      Procedures | 12 |
|    |                       |   |   |
| Part II | Other      Information     |   |
|    |                       |   |   |
|    | Item 1.                    | Legal      Proceedings | 13 |
|    |                       |   |   |
|    | Item 2.                    | Unregistered Sales of Equity      Securities and Use of Proceeds | 13 |
|    |                       |   |   |
|    | Item 3.                    | Defaults Upon Senior      Securities | 13 |
|    |                       |   |   |
|    | Item 4.                    | Submission of Matters to a Vote of      Security Holders | 13 |
|    |                       |   |   |
|    | Item 5.                    | Other      Information | 13 |
|    |                       |   |   |
|    | Item 6.                    | Exhibits | 14 |
|    |                       |   |   |

----

|                                                                                                 |   |             |     |   |      |   |
|------------------------------------------------------------------------------------------------------|--------|------------------|----------|--------|-----------|--------|
|                                                                                                 |   | September    30, |     |   | March 31, |   |
|                                                                                                 |   | 2007             |     |   | 2007      |   |
|                                                                                                 |   | (Unaudited)      |     |   |      |   |
| ASSETS                                                                                               |   |             |     |   |      |   |
|                                                                                                 |   |             |     |   |      |   |
| Current    assets:                                                                                   |   |             |     |   |      |   |
|     Cash and      cash equivalents                                               |   | $                | --       |   |      | $      | -- |   |
| Totalassets                                                                                          |   | $                | --       |   |      | $      | -- |   |
|                                                                                                 |   |             |     |   |      |   |   |   |
| LIABILITIES AND SHAREHOLDERS'      DEFICIT                                                           |   |             |     |   |      |   |   |   |
|                                                                                                 |   |             |     |   |      |   |   |   |
| Current      liabilities:                                                                            |   |             |     |   |      |   |   |   |
|     Accounts      payable and accrued expenses                                   |   | $                | 124,870  |   |      | $      | 101,372 |   |
|     Convertible      notes payable                                               |   |             | 20,914   |   |      |   | 20,914 |   |
|         Total      current liabilities                       |   |             | 145,784  |   |      |   | 122,286 |   |
|                                                                                                 |   |             |     |   |      |   |   |   |
| Shareholders'      deficit:                                                                          |   |             |     |   |      |   |   |   |
|     Preferred      stock, no par value, 10,000,000 shares authorized,            |   |             | --       |   |      |   | -- |   |
|       no      shares issued or outstanding                             |   |             |     |   |      |   |   |   |
|     Common      stock, no par value, 500,000,000 shares authorized,              |   |             |     |   |      |   |   |   |
|       81,352,500      issued and outstanding at September 30, 2007 and |   |             |     |   |      |   |   |   |
|       March      31, 2007, respectively                                |   |             | 1,000    |   |      |   | 1,000 |   |
|     Deficit      accumulated in the developmental stage                          |   |             | (146,784 | )      |      |   | (123,286 | ) |
|          Total      shareholders’ deficit         |   |             | (145,784 | )      |      |   | (122,286 | ) |
| Total liabilities and      shareholders' deficit                                                     |   | $                | --       |   |      | $      | -- |   |

----

|                                                                   |   |                    |       |   |                    |   |       |                       |   |   |                    |   |   | Cumulative from      Inception |       |
|------------------------------------------------------------------------|--------|-------------------------|------------|--------|-------------------------|--------|------------|----------------------------|--------|--------|-------------------------|--------|--------|--------------------------------|------------|
|                                                                   |   | Three Months      Ended |       |   | Six Months      Ended   |   |       | (February 15,      2005)to |   |
|                                                                   |   | September 30,      2007 |       |   | September 30,      2006 |   |       | September 30,      2007    |   |   | September 30,      2006 |   |   | September 30,      2007        |       |
|                                                                   |   |                    |       |   |                    |   |       |                       |   |   |                    |   |   |                           |       |
| General and administrative      expenses                               |   | $                       | 11,223     |   |                    | $      | 11,264     |                       |   | $      | 22,452                  |   |   | $                              | 23,615     |   |   | $ | 144,014 |   |
|                                                                   |   |                    |       |   |                    |   |       |                       |   |   |                    |   |   |                           |       |   |   |   |   |   |
| Loss from      operations                                              |   |                    | (11,223    | )      |                    |   | (11,264    | )                          |   |   | (22,452                 | )      |   |                           | (23,615    | ) |   |   | (144,014 | ) |
|                                                                   |   |                    |       |   |                    |   |       |                       |   |   |                    |   |   |                           |       |   |   |   |   |   |
| Other income      (expense)                                            |   |                    |       |   |                    |   |       |                       |   |   |                    |   |   |                           |       |   |   |   |   |   |
|   Interest      expense                                      |   |                    | (523       | )      |                    |   | (542       | )                          |   |   | (1,046                  | )      |   |                           | (542       | ) |   |   | (2,770 | ) |
|                                                                   |   |                    |       |   |                    |   |       |                       |   |   |                    |   |   |                           |       |   |   |   |   |   |
| Net loss                                                               |   | $                       | ( 11,746   | )      |                    | $      | (11,806    | )                          |   | $      | (23,498                 | )      |   | $                              | (10,024    | ) |   | $ | (146,784 | ) |
|                                                                   |   |                    |       |   |                    |   |       |                       |   |   |                    |   |   |                           |       |   |   |   |   |   |
| Net loss per      share:                                               |   |                    |       |   |                    |   |       |                       |   |   |                    |   |   |                           |       |   |   |   |   |   |
|         Basic      and diluted |   | $                       | --         |   |                    | $      | --         |                       |   | $      | --                      |   |   | $                              | --         |   |   |   |   |   |
|                                                                   |   |                    |       |   |                    |   |       |                       |   |   |                    |   |   |                           |       |   |   |   |   |   |
| Weighted average number of common      shares                          |   |                    |       |   |                    |   |       |                       |   |   |                    |   |   |                           |       |   |   |   |   |   |
|   outstanding:                                               |   |                    |       |   |                    |   |       |                       |   |   |                    |   |   |                           |       |   |   |   |   |   |
|         Basic      and diluted |   |                    | 81,352,500 |   |                    |   | 81,352,500 |                       |   |   | 81,352,500              |   |   |                           | 81,352,500 |   |   |   |   |   |

----

|                                                                                    |   |                    |    |   | Cumulative from      Inception |   |
|-----------------------------------------------------------------------------------------|--------|-------------------------|---------|--------|--------------------------------|--------|
|                                                                                    |   | Six Months      Ended   |    |   | (February 15,      2005)       |   |
|                                                                                    |   | September 30,      2007 |    |   | September 30,      2006        |   |   | to September 30,      2007 |   |
| Cash flows from operating      activities:                                              |   |                    |    |   |                           |   |   |   |   |
|     Net      loss                                                   |   | $                       | (23,498 | )      |                           | $      | (24,157 | ) |   | $ | (146,784 | ) |
|                                                                                    |   |                    |    |   |                           |   |   |   |   |   |   |   |
| Adjustments to reconcile net loss      to cash used in operating activities:            |   |                    |    |   |                           |   |   |   |   |   |   |   |
|    Changes in      assets and liabilities:                               |   |                    |    |   |                           |   |   |   |   |   |   |   |
|        Accounts      payable and accrued liabilities |   |                    | 23,498  |   |                           |   | 3,618 |   |   |   | 124,870 |   |
| Net cash used in operating      activities                                              |   |                    | --      |   |                           |   | (20,539 | ) |   |   | (21,914 | ) |
|                                                                                    |   |                    |    |   |                           |   |   |   |   |   |   |   |
| Cash flows from investing      activities                                               |   |                    | --      |   |                           |   | -- |   |   |   | -- |   |
|                                                                                    |   |                    |    |   |                           |   |   |   |   |   |   |   |
| Cash flows from financing      activities:                                              |   |                    |    |   |                           |   |   |   |   |   |   |   |
|     Proceeds      from issuance of convertible notes                |   |                    | --      |   |                           |   | 25,000 |   |   |   | 25,000 |   |
|     Repayment      of convertible notes payable                     |   |                    | --      |   |                           |   | -- |   |   |   | (4,086 | ) |
|     Collection      of stock subscription receivable                |   |                    | --      |   |                           |   | -- |   |   |   | 1,000 |   |
| Net cash provided by financing      activities                                          |   |                    | --      |   |                           |   | 25,000 |   |   |   | 21,914 |   |
|                                                                                    |   |                    |    |   |                           |   |   |   |   |   |   |   |
| Net increase in      cash                                                               |   |                    | --      |   |                           |   | 4,461 |   |   |   | -- |   |
|                                                                                    |   |                    |    |   |                           |   |   |   |   |   |   |   |
| Cash and cash equivalents,      beginning of period                                     |   |                    | --      |   |                           |   | 1,944 |   |   |   | -- |   |
|                                                                                    |   |                    |    |   |                           |   |   |   |   |   |   |   |
| Cash and cash equivalents, end of      period                                           |   | $                       | --      |   |                           | $      | 6,405 |   |   | $ | -- |   |
|                                                                                    |   |                    |    |   |                           |   |   |   |   |   |   |   |
| Supplemental cash flow      information:                                                |   |                    |    |   |                           |   |   |   |   |   |   |   |
| Interest    paid                                                                        |   | $                       | --      |   |                           | $      | -- |   |   | $ | -- |   |
| Taxes paid                                                                              |   | $                       | --      |   |                           | $      | -- |   |   | $ | -- |   |

----

----

----

|   | Recent Sales of Unregistered      Securities |
|--------|----------------------------------------------|

----

| Exhibit No. | Description                                                                                                                                                                                                                                    |
|-------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 3.1         | Articles of Incorporation      (incorporated by reference to Exhibit 3.1 from Registration Statement on      Form–SB filed with the Securities and Exchange Commission on October 11,      2000)                                         |
| 3.2         | Amended Articles of Incorporation      (filed herewith)                                                                                                                                                                                        |
| 3.3         | Bylaws of Tabatha I, Inc.      (incorporated by reference to Exhibit 3.2 from Registration Statement on      Form–SB filed with the Securities and Exchange Commission on October 11,      2000)                                         |
| 4.1         | Specimen of Stock Certificate      (incorporated by reference to Exhibit 4.1 from Registration Statement on      Form–SB filed with the Securities and Exchange Commission on October 11,      2000)                                     |
| 4.2         | Specimen Class A Convertible      Preferred Stock Certificate (incorporated by reference to Exhibit 4.2 from      Registration Statement on Form–SB filed with the Securities and Exchange      Commission on October 11, 2000)          |
| 14.1        | Code of Ethics (incorporated by      reference to Exhibit 14.1 to Registrant’s Form 10-KSB filed with the      Securities and Exchange Commission June 29,2005)                                                                          |
| 10.1        | Exchange Agreement between Tabatha      I, Inc. and Zigen, Inc. dated February 25, 2005 (incorporated by reference      to Exhibit 10.1 to Registrant’s Form 8-K filed with the Securities and      Exchange Commission on May 31, 2005) |
| 10.2        | 2005 Amended and Restated Stock      Option (incorporated by reference to Exhibit A to Registrant’s Definitive      Information Statement filed with the Securities and Exchange Commission on      July 1, 2005)                        |
| 21.1        | List of Subsidiaries (filed      herewith)                                                                                                                                                                                                     |
| 31.1        | Certification pursuant to Rule      13a-14(a) or 15d-14(a) under the Securities Exchange Act of 1934, as      amended (filed herewith)                                                                                                         |
| 32.1        | Certification pursuant to 18      U.S.C. Section 1350, as adopted pursuant to Section 906 of the      Sarbanes-Oxley Act of 2002 (filed  herewith)                                                                                             |

----

----